Applied Health Economics and Health Policy

Article	Citations
Productivity Losses due to Health Problems Arising from COVID-19 Pandemic: A Systematic Review of Population-Level Studies Worldwide	91
Approaches to Incorporation of Preferences into Health Economic Models of Genomic Medicine: A Critical Interpretive Synthesis and Conceptual Framework	89
Australian Preferences for Prenatal Screening: A Discrete Choice Experiment Comparing Metropolitan and Rural/Regional Areas	41
Korean Guidelines for Pharmacoeconomic Evaluations: Updates in the Third Version	33
Comment on: “Willingness to Pay for a COVID-19 Vaccine”	32
Values in Modelling: Video Series Development and Evaluation Survey	32
Effect of Competition on Generic Drug Prices	28
Measurement of Health-Related Quality of Life from Conception to Postpartum Using the EQ-5D-5L Among a National Sample of US Pregnant and Postpartum Adults	28
Cost Effectiveness of Denosumab for Secondary Prevention of Osteoporotic Fractures Among Postmenopausal Women in China: An Individual-Level Simulation Analysis	27
Health Interventions May Have Divergent Impacts on Health and Economic Equity: A Case Study of the Community-Based Hypertension Improvement Project in Ghana	25
Developing a Framework for the Health Technology Assessment of Histology-independent Precision Oncology Therapies	22
Are Drug Novelty Characteristics Associated With Greater Health Benefits?	21
Projected Impact on Labour Productivity Costs of Cancer-Related Premature Mortality in Europe 2018–2040	21
Cost-Utility Analysis of TNF-α Inhibitors, B Cell Inhibitors, and JAK Inhibitors Versus csDMARDs for Rheumatoid Arthritis Treatment	20
Does the Choice of Health Metric, DALY or QALY, Influence Conclusions of Health Economic Evaluation? A Case Study of Rotavirus Vaccine in Burundi	20
Herd Immunity Effects in Cost-Effectiveness Analyses among Low- and Middle-Income Countries	19
Economic Evaluations of Preventive Interventions for Dental Caries and Periodontitis: A Systematic Review	19
Cost-Utility Analysis of Major System Change in Specialist Cancer Surgery in London, England, Using Linked Patient-Level Electronic Health Records and Difference-in-Differences Analysis	17
Cost-Effectiveness of Anti-retroviral Adherence Interventions for People Living with HIV: A Systematic Review of Decision Analytical Models	17
Evidence Synthesis and Linkage for Modelling the Cost-Effectiveness of Diagnostic Tests: Preliminary Good Practice Recommendations	15
Authors’ Reply to Gandjour: “10 Years of AMNOG: What is the Willingness-to-Pay for Pharmaceuticals in Germany?”	15
An Economic Model for Estimating Trial Costs with an Application to Placebo Surgery Trials	14
A Comparative Analysis of Anticancer Drug Appraisals Including Managed Entry Agreements in South Korea and England	13
Cost-Effectiveness Analysis of Stockholm 3 Testing Compared to PSA as the Primary Blood Test in the Prostate Cancer Diagnostic Pathway: A Decision Tree Approach	13
Rationing in an Era of Multiple Tight Constraints: Is Cost-Utility Analysis Still Fit for Purpose?	13

A structured process for the validation of a decision-analytic model: application to a cost-effectiveness model for risk-stratified national breast screening	12
A Model-Based Estimate of the Cost-Effectiveness Threshold in Germany	12
Cost-Effective and Sustainable Drug Use in Hospitals: A Systematic and Practice-Based Approach	12
Value and Price of Multi-indication Cancer Drugs in the USA, Germany, France, England, Canada, Australia, and Scotland	12
Financial Incentives in the Path to Recovery from the COVID-19 Pandemic	12
Approaches to Measure Efficiency in Primary Care: A Systematic Literature Review	11
Review and Assessment of Policy Options for Improving Access to Combination Therapies in Oncology in Europe	11
Population Norms for SF-6Dv2 and EQ-5D-5L in China	11
Using Economics to Impact Local Obesity Policy: Introducing the UK Centre for Economics of Obesity (CEO)	11
The Gift of Time, How Do I Want to Spend It? Exploring Preferences for Time Allocation Among Women with and without a Breast Cancer Diagnosis	10
Correction: Economic Evaluations of Robotic-Assisted Surgery: Methods, Challenges and Opportunities	10
Systematic Review of the Psychometric Performance of Generic Childhood Multi-attribute Utility Instruments	10
COVID-19 Vaccine Demand and Financial Incentives	10
A Contingent Valuation Study for Use in Valuing Public Goods with Health Externalities: The Case of Street Pianos	10
A Systematic Review of the Costs Relating to Non-pharmaceutical Interventions Against Infectious Disease Outbreaks	10
Simplified Methods for Modelling Dependent Parameters in Health Economic Evaluations: A Tutorial	9
Cost‑Effectiveness of Lorlatinib in First-Line Treatment of Adult Patients with Anaplastic Lymphoma Kinase (ALK)‑Positive Non‑Small‑Cell Lung Cancer in Sweden	9
Incorporating Process Utility into Cost-Effectiveness Analysis via a Bolt-On Domain to the SF-6D: An Exploratory Study	9
Correction to: Cost-Effectiveness of Once-Weekly Semaglutide 1 mg versus Canaglifozin 300 mg in Patients with Type 2 Diabetes Mellitus in a Canadian Setting	9
Assessing the Direct Impact of Death on Discrete Choice Experiment Utilities	8
Methods and Practical Considerations for Conducting Budget Impact Analysis for Non-Pharmaceutical Interventions	8
Deterministic and Probabilistic Analysis of a Simple Markov Model: How Different Could They Be?	8
Cost-Effectiveness of Perinatal Depression Screening: A Scoping Review	8
Acknowledgement to Referees	7
Cost Effectiveness of Molecular Diagnostic Testing Algorithms for the Treatment Selection of Frontline Ibrutinib for Patients with Chronic Lymphocytic Leukemia in Australia	7
Economic Evaluation of Oral Nucleos(t)ide Analogues for Patients with Chronic Hepatitis B in Thailand	7
Comparing Preferences for Disease Profiles: A Discrete Choice Experiment from a US Societal Perspective	7
Conditional Funding Recommendations for Drugs in Canada: A Cross-Sectional Analysis	7
Population-Based Testing for Undiagnosed Hepatitis C: A Systematic Review of Economic Evaluations	6
Preferred Attributes of Care Pathways for Obstructive Sleep Apnoea from the Perspective of Diagnosed Patients and High-Risk Individuals: A Discrete Choice Experiment	6
Exploratory Cost-Utility Analysis of a 37-Gene Panel Versus Usual Care to Guide Therapy for Patients with Intermediate-Risk Myeloid Malignancies	6
Pharmaceutical Patents in Europe: Radical Reforms Rather Than Getting Rid?	6
Adding a Gene Expression Profile Test to Aid Differential Diagnosis and Treatment in Aggressive Large B-Cell Lymphoma: An Early Exploratory Economic Evaluation	6
The Impact of Suboxone’s Market Exclusivity on Cost of Opioid Use Disorder Treatment	6
The Effects of School Closures on COVID-19: A Cross-Country Panel Analysis	6
The Effect of Price Changes and Teaspoon Labelling on Intention to Purchase Sugar-Sweetened Beverages: A Discrete Choice Experiment	6
Episcissors-60 for Mediolateral Episiotomy: Evaluation of Clinical and Economic Evidence to Inform NICE Medical Technologies Guidance	6
The Broader Opportunity Costs in the Broader Cost-Effectiveness Analysis Framework	6
Economic Evaluation of Evusheld for Preexposure Prevention of COVID-19 in High-Risk Populations: Early Evidence from Thailand	6
‘What You See is All There is’: The Importance of Heuristics in Cost-Benefit Analysis (CBA) and Social Return on Investment (SROI) in the Evaluation of Public Health Interventions	6
Societal Cost of Racial Pneumococcal Disease Disparities in US Adults Aged 50 Years or Older	6
Prices of Orphan Drugs in Four Western European Countries Before and After Market Exclusivity Expiry: A Cross-Country Comparison of List Prices and Purchase Prices	6
Budget Impact Analysis of the FreeStyle Libre Flash Continuous Glucose Monitoring System® in Patients with Type 1 Diabetes Mellitus and Type 2 Diabetes Mellitus with Multiple Daily Insulin Injections	6
Challenges in the Evaluation of Emerging Highly Specialised Technologies: Is There a Role for Living HTA?	6
Cost of Carbon in the Total Cost of Healthcare Procedures: A Methodological Challenge	5
National Methodological Guidelines to Conduct Budget Impact Analysis for Health Technology Assessment in India	5
The Impact of the Approach to Accounting for Age and Sex in Economic Models on Predicted Quality-Adjusted Life-Years	5
A Review of Current Approaches to Evaluating and Reimbursing New Medicines in a Subset of OECD Countries	5
Cost Effectiveness of Deep Brain Stimulation for Parkinson’s Disease: A Systematic Review	5
The Hidden Toll of Psychological Distress in Australian Adults and Its Impact on Health-Related Quality of Life Measured as Health State Utilities	5

Is There Broad-Based Support in High-Income Countries for COVID-19 Vaccine Donation? Evidence from Seven Countries	5
Willingness to Pay for National Health Insurance: A Contingent Valuation Study Among Patients Visiting Public Hospitals in Melaka, Malaysia	5
Psychometric Evaluation of the PedsQL GCS and CHU9D in Australian Children and Adolescents with Common Chronic Health Conditions	5
A Systematic Review on Economic Evaluation Studies of Diagnostic and Therapeutic Interventions in the Middle East and North Africa	5
Measurement of Catastrophic Health Expenditure in India: A Systematic Review and Meta-Analysis	5
Preferences for Medical Consultations from Online Providers: Evidence from a Discrete Choice Experiment in the United Kingdom	5
Applications of Behavioral Economics to Pharmaceutical Policymaking: A Scoping Review with Implications for Best-Value Biological Medicines	5
Analysing the Efficiency of Health Systems: A Systematic Review of the Literature	5
Exploratory Approach to Incorporating Carbon Footprint in Health Technology Assessment (HTA) Modelling: Cost-Effectiveness Analysis of Health Interventions in the United Kingdom	5
The Danish EQ-5D-5L Value Set: A Hybrid Model Using cTTO and DCE Data	5
Comparison of the Measurement Properties of EQ-5D-5L and SF-6Dv2 in COVID-19 Patients in China	5
The Value of New: Consideration of Product Novelty in Health Technology Assessments of Pharmaceuticals	4
Quality-Adjusted Life Expectancy Norms Based on the EQ-5D-5L and SF-6Dv2 for China	4
Use of Cost-Effectiveness Thresholds in Healthcare Public Policy: Progress and Challenges	4
Incidence of Catastrophic Health Expenditure and Its Determinants in Cancer Patients: A Systematic Review and Meta-analysis	4
Cost Effectiveness of Allogeneic Umbilical Cord Blood-Derived Mesenchymal Stem Cells in Patients with Knee Osteoarthritis	4
The Development of a New Approach for the Harmonized Multi-Sectoral and Multi-Country Cost Valuation of Services: The PECUNIA Reference Unit Cost (RUC) Templates	4
Information Asymmetry in Hospitals: Evidence of the Lack of Cost Awareness in Clinicians	4
Economic Epidemiology: A Framework to Study Interactions of Epidemics and the Economy	4
Cost-Effectiveness of Once-Weekly Semaglutide 1 mg versus Canagliflozin 300 mg in Patients with Type 2 Diabetes Mellitus in a Canadian Setting	4
Correction to: The Cost Effectiveness of Taxation of Sugary Foods and Beverages: A Systematic Review of Economic Evaluations	4
Productivity Loss and Indirect Costs for Patients Newly Diagnosed with Early- versus Late-Stage Cancer in the USA: A Large-Scale Observational Research Study	4
A Guideline-Implementation Intervention to Improve the Management of Low Back Pain in Primary Care: A Difference-in-Difference-in-Differences Analysis	4
Sedaconda ACD-S for Sedation with Volatile Anaesthetics in Intensive Care: A NICE Medical Technologies Guidance	4
Correction to: Incidence of Catastrophic Health Expenditure and Its Determinants in Cancer Patients: A Systematic Review and Meta‑analysis	4
Correction to: The False Economy of Seeking to Eliminate Delayed Transfers of Care: Some Lessons from Queueing Theory	4
Cost-Effectiveness Analysis of Temocillin Treatment in Patients with Febrile UTI Accounting for the Emergence of Antibiotic Resistance	4
Treatment Preferences of Adolescents and Young Adults with Depressive Symptoms: A Discrete Choice Experiment	3
The Economic Cost of Rising Non-communicable Diseases in India: A Systematic Literature Review of Methods and Estimates	3
What Interventions are Cost Effective in Reducing Violence Against Women? A Scoping Review	3
The Limitations and Potentials of Evaluating Economic Aspects of Community-Based Health Promotion: A Critical Review	3
EQ-5D-5L Population Norms for Italy	3
Avoiding Opportunity Cost Neglect in Cost-Effectiveness Analysis for Health Technology Assessment	3
Cost Effectiveness of Pharmacological Management for Osteoarthritis: A Systematic Review	3
10 Years of AMNOG: What is the Willingness-to-Pay for Pharmaceuticals in Germany?	3
A Case Study on Reviewing Specialist Services Commissioning in Wales: TAVI for Severe Aortic Stenosis	3
The Impact of Raising Alcohol Taxes on Government Tax Revenue: Insights from Five European Countries	3
Local Level Economic Evaluation: What is it? What is its Value? Is it Sustainable?	3
Health technology assessment – an important opportunity to inform the use of medical devices in the paediatric population: an analysis of NICE Medical Technology Guidance	3
Financing and Reimbursement Models for Personalised Medicine: A Systematic Review to Identify Current Models and Future Options	3
A Systematic Review of the World’s Largest Government Sponsored Health Insurance Scheme for 500 Million Beneficiaries in India: Pradhan Mantri Jan Arogya Yojana	3
Forecasting the Incremental Value to Society Created by a Class of New Prescription Drugs: A Proposed Methodology and Its Application to Treating Chronic Hepatitis C in India	3
Cost-effectiveness Analysis of the Dental RECUR Pragmatic Randomized Controlled Trial: Evaluating a Goal-oriented Talking Intervention to Prevent Reoccurrence of Dental Caries in Children	3
Economic Evaluation of Triple Therapy with Budesonide/Glycopyrrolate/Formoterol Fumarate for the Treatment of Moderate to Very Severe Chronic Obstructive Pulmonary Disease in China Using a Semi-Markov	3
Are Web-Based Valuation Surveys for Preference-Based Measures as Reliable as Face-to-Face Surveys? TTO, DCE and DCE with Duration	3
Informing Structural Assumptions for Three State Oncology Cost-Effectiveness Models through Model Efficiency and Fit	3
A Systematic Review of Kidney Transplantation Decision Modelling Studies	3
VOLY: The Monetary Value of a Life-Year at the End of Patients’ Lives	3
The Inflation Reduction Act: Hope for Prescription Drug Prices in the USA	3
Willingness to Pay for One Additional Quality Adjusted Life Year: A Population Based Survey from China	3
ENTIMOS: A Discrete Event Simulation Model for Maximising Efficiency of Infusion Suites in Centres Treating Multiple Sclerosis Patients	2
Different Frameworks, Similar Results? Head-to-Head Comparison of the Generic Preference-Based Health-Outcome Measures CS-Base and EQ-5D-5L	2
The Sandbox Approach and its Potential for Use in Health Technology Assessment: A Literature Review	2
Consumers' Preferences and Willingness to Pay for Personalised Nutrition	2
Evaluating Health Inequality in Five Caribbean Basin Countries Using EQ-5D-5L	2
Economic Consequences of Anti-HCV Treatment of Patients Diagnosed Through Screening in Italy: A Prospective Modelling Analysis	2
A Multi-dimensional Framework of Valued Output for Primary Care in England	2
Headroom Analysis for Early Economic Evaluation: A Systematic Review	2
Population-Level Impact of Omitting Axillary Lymph Node Dissection in Early Breast Cancer Women: Evidence from an Economic Evaluation in Germany	2
Use of Health Technology Assessment for the Continued Funding of Health Technologies: The Case of Immunoglobulins for the Management of Multifocal Motor Neuropathy	2
The Short Form 6 Dimensions (SF-6D): Development and Evolution	2
Public Preference for Off-Label Use of Drugs for Cancer Treatment and Relative Importance of Associated Adverse Events: A Discrete Choice Experiment and Best-Worst Scaling	2
Correction: Exploring the Integration of Environmental Impacts in the Cost Analysis of the Pilot MEL-SELF Trial of Patient-Led Melanoma Surveillance	2
Correction to: Cost Effectiveness of Allogeneic Umbilical Cord Blood-Derived Mesenchymal Stem Cells in Patients with Knee Osteoarthritis	2
Authors’ Reply to Sprengholz and Betsch: “Willingness to Pay for a COVID-19 Vaccine”	2
Determining What Represents Value in the Treatment of Refractory or Unexplained Chronic Cough from the Perspective of Key Stakeholders in Spain Using Multi-Criteria Decision Analysis	2
How Far is Germany From Value-Based Pricing 10 Years After the Introduction of AMNOG?	2
Exploring EQ-5D-Y-3L Experience-Based VAS Values Derived Among Adolescents	2
Economic Evaluation Evidence for Resource-Allocation Decision Making: Bridging the Gap for Local Decision Makers Using English Case Studies	2
Economic Effects of Fixed-Dose Versus Loose-Dose Combination Therapy for Type 2 Diabetes Patients	2
Health Economic Evaluations of Obesity Interventions: Expert Views on How We Can Identify, Interpret, Analyse and Translate Effects	2
Assessing the Value of New Antimicrobials: Evaluations of Cefiderocol and Ceftazidime-Avibactam to Inform Delinked Payments by the NHS in England	2
The False Economy of Seeking to Eliminate Delayed Transfers of Care: Some Lessons from Queueing Theory	2
Evaluating the Cost-Effectiveness of Etranacogene Dezaparvovec Gene Therapy for Hemophilia B Treatment in the USA	2
How is Value Defined in Molecular Testing in Cancer? A Scoping Review	2
Child–Parent Agreement in the Assessment of Health-Related Quality of Life Using the CHU9D and the PedsQLTM	2
Evolving Evidence-Based Value Assessment of One-Time Therapies: Tisagenlecleucel as a Case Study	2
Pricing and Reimbursement of Patent-Protected Medicines: Challenges and Lessons from South-Eastern Europe	2
Financing Comprehensive Immunization Services in Lao PDR: A Fiscal Space Analysis From a Public Policy Perspective	2
Is Using Sodium-Glucose Cotransporter-2 Inhibitors to Treat Adults with Chronic Heart Failure Cost-Effective? A Systematic Review of Cost-Effectiveness Studies	2

Estimating a Drug’s Price After Loss of Exclusivity as a Function of Its Cost of Goods Sold

2